X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) had its price objective boosted by analysts at HC Wainwright from $3.00 to $5.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's target price indicates a potential upside of 346.43% from the stock's current price.
X4 Pharmaceuticals Price Performance
Shares of NASDAQ XFOR traded up $0.03 during midday trading on Tuesday, hitting $1.12. The company had a trading volume of 4,998,824 shares, compared to its average volume of 2,583,256. The company has a quick ratio of 5.34, a current ratio of 5.34 and a debt-to-equity ratio of 1.07. X4 Pharmaceuticals has a twelve month low of $0.57 and a twelve month high of $2.58. The business has a 50-day simple moving average of $1.15 and a two-hundred day simple moving average of $0.93. The firm has a market capitalization of $188.09 million, a price-to-earnings ratio of -1.87 and a beta of 0.48.
X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last announced its earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.05. Equities research analysts anticipate that X4 Pharmaceuticals will post -0.47 earnings per share for the current year.
Insider Transactions at X4 Pharmaceuticals
In other news, CFO Adam S. Mostafa sold 27,721 shares of X4 Pharmaceuticals stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $1.01, for a total transaction of $27,998.21. Following the completion of the sale, the chief financial officer now directly owns 52,500 shares in the company, valued at $53,025. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Paula Ragan sold 49,678 shares of the business's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $0.88, for a total value of $43,716.64. Following the completion of the sale, the chief executive officer now directly owns 765,068 shares in the company, valued at $673,259.84. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Adam S. Mostafa sold 27,721 shares of the business's stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $1.01, for a total transaction of $27,998.21. Following the completion of the sale, the chief financial officer now owns 52,500 shares of the company's stock, valued at $53,025. The disclosure for this sale can be found here. Insiders sold a total of 185,708 shares of company stock worth $170,428 over the last ninety days. 1.08% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On X4 Pharmaceuticals
A number of institutional investors have recently bought and sold shares of XFOR. SG Americas Securities LLC purchased a new stake in X4 Pharmaceuticals in the third quarter valued at approximately $37,000. Barclays PLC grew its stake in X4 Pharmaceuticals by 334.8% during the third quarter. Barclays PLC now owns 382,134 shares of the company's stock worth $417,000 after buying an additional 294,255 shares during the period. Stonepine Capital Management LLC grew its stake in X4 Pharmaceuticals by 14.5% during the third quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company's stock worth $5,748,000 after buying an additional 668,422 shares during the period. GSA Capital Partners LLP purchased a new stake in X4 Pharmaceuticals during the third quarter worth approximately $678,000. Finally, Bain Capital Life Sciences Investors LLC grew its stake in X4 Pharmaceuticals by 6.0% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 16,915,784 shares of the company's stock worth $14,184,000 after buying an additional 955,196 shares during the period. 72.03% of the stock is currently owned by hedge funds and other institutional investors.
X4 Pharmaceuticals Company Profile
(
Get Free Report)
X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.
Featured Stories
Before you consider X4 Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and X4 Pharmaceuticals wasn't on the list.
While X4 Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
